細胞および遺伝子サプライチェーンサービス市場- 世界の産業規模、シェア、動向、機会、予測、技術別、用途別、エンドユーザー別、地域別、競合別、2019年～2029年

世界の細胞および遺伝子サプライチェーンサービス市場は2023年に13億2,000万米ドルと評価され、2029年までのCAGRは9.64%で、予測期間中に力強い成長が予測されています。

世界の細胞および遺伝子サプライチェーンサービス市場は、ヘルスケア産業におけるダイナミックなセクターであり、画期的な細胞・遺伝子治療の需要に応えるべく急速に発展しています。これらの治療法は、その開発、製造、流通過程における独自のニーズに対応する専門的なサプライチェーン・サービスへのかつてない需要を呼び起こしています。この市場の主要プレーヤーには、ロジスティクス企業、専門サービスプロバイダー、製造受託機関（CMO）、先端療法の複雑な取り扱いに合わせた革新的ソリューションを提供するテクノロジー企業などが含まれます。慢性疾患の有病率の上昇、バイオテクノロジーの進歩、個別化医療の浸透といった要因が市場の成長を後押ししています。さらに、COVID-19の大流行により、弾力性があり効率的なサプライチェーンの必要性が強調され、細胞・遺伝子治療領域における堅牢なソリューションに対する需要がさらに高まっています。

また、この業界は、複雑な規制、コールドチェーン管理、サプライチェーン全体における機密性の高い生物材料の完全性とトレーサビリティの確保などの課題に直面しています。その結果、企業はサプライチェーンのプロセスを最適化し、リスクを軽減するために、インフラ、テクノロジー、戦略的パートナーシップに多額の投資を行っています。利害関係者は、環境に優しいソリューションと透明性の高いサプライチェーンの実践を提唱しており、持続可能性と倫理的配慮が重視されるようになっています。今後を展望すると、世界の細胞および遺伝子サプライチェーンサービス市場は、バイオテクノロジーの進歩、研究開発投資の増加、個別化医療構想の世界的拡大に牽引され、大きく成長する見通しです。とはいえ、新たな課題に対処し、この変革の分野における大きな機会を活かすためには、継続的な革新と協力が不可欠です。

主要市場促進要因

細胞・遺伝子治療の進歩

慢性疾患の増加

バイオテクノロジーへの投資拡大

主な市場課題

規制の複雑さ

コールドチェーン管理

拡張性と容量の制約

主要市場動向

技術革新

投資とパートナーシップの拡大

セグメント別の洞察

技術別の洞察

用途別の洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 細胞および遺伝子サプライチェーンサービスの世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別（クラウド型、オンプレミス型）
  • 用途別（注文とスケジューリング、サンプル収集、ロジスティクス、治療後のフォローアップ）
  • エンドユーザー別（バイオバンク/セルバンク、病院、研究機関、細胞治療ラボ、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 技術別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 アジア太平洋地域の細胞および遺伝子サプライチェーンサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の細胞および遺伝子サプライチェーンサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の細胞および遺伝子サプライチェーンサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の細胞および遺伝子サプライチェーンサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの細胞および遺伝子サプライチェーンサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 用途別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品発表（もしあれば）
• M&A（もしあれば）

第13章 細胞および遺伝子サプライチェーンサービスの世界市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Biocair International Limited
• Arvato SE
• Associated Couriers, LLC.
• TrakCel Limited
• Parkoursc Inc.
• DHL
• McKesson Corporation
• Almac Group Limited
• Catalent Inc.
• Biostor Ltd.

第16章 戦略的提言

Global Cell and Gene Supply Chain Services Market was valued at USD 1.32 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 9.64% through 2029. The Global Cell and Gene Supply Chain Services Market represents a dynamic sector within the healthcare industry, rapidly evolving to meet the demands of revolutionary cell and gene therapies. These therapies have sparked unprecedented demand for specialized supply chain services that cater to the unique needs of their development, manufacturing, and distribution processes. Key players in this market include logistics firms, specialized service providers, contract manufacturing organizations (CMOs), and technology companies offering innovative solutions tailored to the complexities of handling advanced therapies. Factors such as the rising prevalence of chronic diseases, biotechnological advancements, and the uptake of personalized medicine drive the market's growth. Furthermore, the COVID-19 pandemic has underscored the necessity for resilient and efficient supply chains, further propelling demand for robust solutions in the cell and gene therapy domain.

Also, the industry faces challenges, including regulatory intricacies, cold chain management, and ensuring the integrity and traceability of sensitive biological materials throughout the supply chain. Consequently, companies are making substantial investments in infrastructure, technology, and strategic partnerships to optimize supply chain processes and mitigate risks. There's a growing emphasis on sustainability and ethical considerations, with stakeholders advocating for environmentally friendly solutions and transparent supply chain practices. Looking ahead, the Global Cell and Gene Supply Chain Services Market is poised for significant growth, driven by ongoing biotechnological advancements, increased research and development investment, and the expansion of personalized medicine initiatives globally. Nevertheless, continuous innovation and collaboration will be critical to addressing emerging challenges and capitalizing on the vast opportunities in this transformative sector.

Key Market Drivers

Advancements in Cell and Gene Therapies

Advancements in cell and gene therapies are driving the growth of the global cell and gene supply chain services market. These therapies represent a groundbreaking approach to treating various diseases by targeting cellular and genetic causes. As research progresses and more therapies enter the market or clinical trials, the demand for specialized supply chain services rises. One key driver is the expanding portfolio of approved therapies and the growing pipeline of candidates in clinical development. This necessitates robust supply chain infrastructure to ensure timely and efficient delivery worldwide. Providers must navigate handling highly sensitive biological materials, strict temperature controls, and regulatory compliance.

Also, advancements in therapies require tailored logistics and distribution solutions. Many therapies have strict storage and transportation requirements, demanding specialized facilities and equipment. Providers invest in expertise and technology to meet these needs and ensure smooth delivery from manufacturing to clinical sites or patients' homes. As therapies become more prevalent, there's a focus on scaling up production. This requires scalable and flexible supply chain solutions to manage fluctuations in volume while ensuring quality and safety. Providers employ automation, robotics, and data analytics to optimize processes, manage inventory, and enhance visibility and transparency.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a significant driver fueling the growth of the global cell and gene supply chain services market. Chronic diseases, such as cancer, cardiovascular diseases, diabetes, and autoimmune disorders, pose a significant public health challenge worldwide, contributing to a substantial burden on healthcare systems and economies. As traditional treatment options often fall short in providing long-term solutions for these conditions, there is a growing demand for innovative therapies, including cell and gene therapies, that offer the potential for durable and personalized treatments.

The rise in chronic diseases is driving the development and adoption of cell and gene therapies as promising new treatment modalities. These advanced therapies target the underlying causes of diseases at the cellular and genetic levels, offering the potential to address unmet medical needs and provide more effective and targeted treatments for patients. With increasing recognition of the potential of cell and gene therapies to revolutionize healthcare, there is a growing pipeline of therapies in development targeting a wide range of chronic diseases.

As the demand for cell and gene therapies continues to grow, so does the need for specialized supply chain services to support their development, manufacturing, and distribution. The complexity and sensitivity of these therapies require stringent handling and storage conditions, as well as specialized logistics and transportation solutions to ensure their safe and efficient delivery to patients. Supply chain providers play a critical role in managing the logistics and distribution of these therapies, ensuring they reach patients in a timely and reliable manner while maintaining their potency and efficacy.

Moreover, the increasing prevalence of chronic diseases is driving investment and innovation in the biopharmaceutical industry, leading to advancements in manufacturing technologies and processes for cell and gene therapies. As manufacturing capacity expands to meet growing demand, supply chain providers must develop scalable and flexible solutions to support the efficient production and distribution of these therapies. This includes investing in state-of-the-art manufacturing facilities, automation technologies, and quality assurance systems to ensure product quality and compliance with regulatory requirements.

Growing Investment in Biotechnology

The growing investment in biotechnology is a key driver fueling the expansion of the global cell and gene supply chain services market. Biotechnology companies, pharmaceutical firms, and research institutions are increasingly channeling resources into the development of innovative therapies, particularly in the field of cell and gene therapy. This surge in investment is driven by several factors, including advances in scientific research, promising clinical trial results, and the potential for transformative treatments for a wide range of diseases.

Investment in biotechnology is driving the development and commercialization of a diverse array of cell and gene therapies targeting various medical conditions, such as cancer, genetic disorders, and autoimmune diseases. These therapies offer the potential for personalized and precise treatments that can address the underlying causes of diseases at the cellular and genetic levels. As a result, there is a growing pipeline of cell and gene therapies in various stages of development, ranging from early-stage research to late-stage clinical trials.

The increasing investment in biotechnology is also spurring growth in manufacturing capacity and infrastructure to support the production of cell and gene therapies at scale. Biopharmaceutical companies and contract manufacturing organizations (CMOs) are expanding their manufacturing facilities and investing in advanced technologies to meet the growing demand for these therapies. This expansion in manufacturing capacity creates opportunities for supply chain providers to offer specialized services to support the production, storage, and distribution of cell and gene therapies.

Furthermore, the growing investment in biotechnology is driving innovation in supply chain management and logistics to meet the unique requirements of cell and gene therapies. These therapies often have specific handling and storage requirements, such as cryogenic storage or strict temperature controls, to maintain their stability and efficacy. Supply chain providers are developing specialized solutions to meet these requirements, including temperature-controlled transportation, cold chain logistics, and quality assurance systems to ensure the integrity of these sensitive products throughout the supply chain.

Key Market Challenges

Regulatory Complexities

Regulatory complexities pose a significant challenge for stakeholders in the cell and gene supply chain services market. The development and commercialization of cell and gene therapies are subject to stringent regulations and oversight by regulatory agencies worldwide. Navigating these regulatory requirements can be challenging, particularly given the evolving nature of the field and the unique characteristics of these therapies. Ensuring compliance with regulations adds complexity to supply chain operations, requiring robust quality assurance systems, documentation, and processes to meet regulatory standards.

Cold Chain Management

Cold chain management presents a considerable challenge in the cell and gene supply chain services market. Many cell and gene therapies have strict temperature requirements to maintain their stability and efficacy. Ensuring the integrity of these therapies throughout the supply chain, from manufacturing to delivery to the patient, requires sophisticated cold chain logistics and storage solutions. Maintaining the required temperature conditions during transportation and storage poses logistical challenges, particularly for products with ultra-low temperature requirements or long-distance distribution networks.

Scalability and Capacity Constraints

Scalability and capacity constraints pose significant challenges in the cell and gene supply chain services market. As the demand for cell and gene therapies continues to grow, there is increasing pressure on manufacturing and distribution capacity to meet market needs. Scaling up production while maintaining product quality and compliance with regulatory requirements is a complex endeavor that requires substantial investment in infrastructure, technology, and expertise. Additionally, fluctuations in demand and production volumes can strain existing capacity and lead to bottlenecks in the supply chain.

Key Market Trends

Technological Innovations

One of the critical challenges in the cell and gene supply chain is maintaining the integrity and efficacy of these therapies, which often require precise temperature control. Technological innovations in temperature-controlled logistics solutions are addressing this challenge by providing advanced monitoring and control systems to ensure that therapies remain within the required temperature range throughout the supply chain. These solutions leverage sensors, data analytics, and real-time monitoring to detect and mitigate temperature excursions, thereby safeguarding product quality and patient safety.

Blockchain technology is revolutionizing supply chain management by providing a transparent and immutable record of product movement and transactions. In the cell and gene supply chain services market, blockchain-based traceability platforms are enhancing transparency, security, and traceability across the entire value chain. These platforms enable stakeholders to track the journey of therapies from manufacturing facilities to patients, ensuring compliance with regulatory requirements and minimizing the risk of counterfeiting or fraud. By providing a decentralized and tamper-proof record of transactions, blockchain technology enhances trust and accountability in the supply chain ecosystem.

Automation and robotics are driving efficiency and scalability in the cell and gene supply chain services market. Automated systems streamline manufacturing processes, reduce human error, and increase throughput, enabling companies to scale up production to meet growing demand. Robotics technology is also being utilized in warehouse management and logistics operations to improve inventory management, order fulfillment, and transportation. By automating repetitive tasks and optimizing workflows, automation and robotics technologies enhance productivity and reduce costs throughout the supply chain.

Data analytics and artificial intelligence (AI) are revolutionizing decision-making in the cell and gene supply chain services market. Advanced analytics tools enable stakeholders to analyze vast amounts of data generated throughout the supply chain, identify trends, and optimize operations in real time. AI-powered algorithms can predict demand, optimize inventory levels, and improve route planning for transportation, thereby enhancing efficiency and reducing costs. By leveraging data analytics and AI, supply chain providers can gain valuable insights into their operations, improve decision-making, and drive continuous improvement across the entire supply chain.

Growing Investment and Partnerships

The global cell and gene supply chain services market is experiencing a significant boost due to growing investment and strategic partnerships among stakeholders. As cell and gene therapies emerge as promising treatment modalities for various diseases, companies across the biopharmaceutical and logistics sectors are increasing their investments and forming partnerships to address the unique challenges associated with the supply chain for these advanced therapies. One of the key drivers of the growth in investment is the expanding pipeline of cell and gene therapies in development. Pharmaceutical companies, biotech startups, and academic institutions are investing heavily in research and development to advance these therapies through clinical trials and regulatory approval processes. As the number of therapies in the pipeline increases, so does the demand for specialized supply chain services to support their manufacturing, storage, and distribution.

In addition to direct investment in research and development, companies are also investing in infrastructure and technology to enhance the efficiency and reliability of the supply chain for cell and gene therapies. This includes investments in manufacturing facilities, cold chain logistics, and quality assurance systems to ensure the safe and timely delivery of therapies to patients worldwide. By investing in infrastructure and technology, companies can improve the scalability, flexibility, and resilience of the supply chain, thereby accelerating the commercialization and adoption of cell and gene therapies.

Strategic partnerships are also playing a crucial role in driving growth in the cell and gene supply chain services market. Companies are forming partnerships with other stakeholders, including logistics providers, technology firms, and regulatory agencies, to collaborate on developing innovative solutions to address the unique challenges of the supply chain for cell and gene therapies. These partnerships enable companies to leverage each other's expertise, resources, and networks to overcome barriers and drive progress in the field.

Furthermore, partnerships between biopharmaceutical companies and contract manufacturing organizations (CMOs) are becoming increasingly common as companies seek to scale up production and meet growing demand for cell and gene therapies. By partnering with CMOs, companies can access specialized manufacturing capabilities and expertise, allowing them to bring therapies to market more quickly and efficiently.

Segmental Insights

Technology Insights

Based on the technology, presence on cloud segment emerged as the dominant segment in the global cell and gene supply chain services market in 2023. This can be attributed to several factors including its scalability, real-time visibility, collaboration capabilities, and accessibility, which collectively drive efficiency, innovation, and growth in the cell and gene therapy supply chain ecosystem.

Application Insights

Based on the application, logistics segment emerged as the dominant segment in the global cell and gene supply chain services market in 2023. The dominance of the logistics segment in the Global Cell and Gene Supply Chain Services market in 2023 underscores its critical role in ensuring the efficient and reliable delivery of cell and gene therapies. Advanced logistics solutions enable providers to navigate regulatory complexities, optimize supply chain efficiency, and ensure the safe transportation of therapies, ultimately driving growth and innovation in the cell and gene therapy ecosystem

Regional Insights

North America emerged as the dominant player in the global cell and gene supply chain services market in 2023, holding the largest market share. North America boasts advanced infrastructure and logistics capabilities, making it well-equipped to support the complex supply chain requirements of cell and gene therapies. The region has a dense network of manufacturing facilities, distribution centers, and transportation networks, facilitating the efficient and timely delivery of therapies to patients across the continent and beyond. Furthermore, North America leads the world in biotechnology innovation and investment, with a thriving ecosystem of biopharmaceutical companies, research institutions, and academic centers.

Key Market Players

Biocair International Limited

Arvato SE

Associated Couriers, LLC.

TrakCel Limited

Parkoursc Inc.

DHL

McKesson Corporation

Almac Group Limited

Catalent Inc.

Biostor Ltd.

Report Scope:

In this report, the Global Cell and Gene Supply Chain Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Cell and Gene Supply Chain Services Market, By Technology:

Presence on cloud Presence on-premises

Global Cell and Gene Supply Chain Services Market, By Applications:

Ordering and scheduling Sample collection Logistics Post treatment follow-up

Global Cell and Gene Supply Chain Services Market, By End-User:

Biobank/ cell-bank Hospitals Research institutes Cell therapy labs Others

Global Cell and Gene Supply Chain Services Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Supply Chain Services Market.

Available Customizations:

Global Cell and Gene Supply Chain Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Cell and Gene Supply Chain Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Presence on cloud, Presence on-premises)
  • 5.2.2. By Applications (Ordering and scheduling, Sample collection, Logistics, Post treatment follow-up)
  • 5.2.3. By End User (Biobank/ cell-bank, Hospitals, Research institutes, Cell therapy labs, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Technology
  • 5.3.2. By Applications
  • 5.3.3. By End User
  • 5.3.4. By Region

6. Asia Pacific Cell and Gene Supply Chain Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Applications
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Cell and Gene Supply Chain Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Applications
      • 6.3.1.2.3. By End User
  • 6.3.2. India Cell and Gene Supply Chain Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Applications
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Cell and Gene Supply Chain Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Applications
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Cell and Gene Supply Chain Services Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Technology
      • 6.3.4.2.2. By Applications
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Cell and Gene Supply Chain Services Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Technology
      • 6.3.5.2.2. By Applications
      • 6.3.5.2.3. By End User

7. Europe Cell and Gene Supply Chain Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Applications
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cell and Gene Supply Chain Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Applications
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Cell and Gene Supply Chain Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Applications
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Cell and Gene Supply Chain Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Applications
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cell and Gene Supply Chain Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Applications
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Cell and Gene Supply Chain Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Applications
      • 7.3.5.2.3. By End User

8. North America Cell and Gene Supply Chain Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Applications
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Cell and Gene Supply Chain Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Applications
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Cell and Gene Supply Chain Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Applications
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Cell and Gene Supply Chain Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Applications
      • 8.3.3.2.3. By End User

9. South America Cell and Gene Supply Chain Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Applications
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cell and Gene Supply Chain Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Applications
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Cell and Gene Supply Chain Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Applications
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Cell and Gene Supply Chain Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Applications
      • 9.3.3.2.3. By End User

10. Middle East and Africa Cell and Gene Supply Chain Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Applications
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cell and Gene Supply Chain Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Applications
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Cell and Gene Supply Chain Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Applications
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Cell and Gene Supply Chain Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Applications
      • 10.3.3.2.3. By End User
  • 10.3.4. Egypt Cell and Gene Supply Chain Services Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Technology
      • 10.3.4.2.2. By Applications
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches ( If Any)
• 12.3. Mergers & Acquisitions ( If Any)

13. Global Cell and Gene Supply Chain Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Biocair International Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Arvato SE
• 15.3. Associated Couriers, LLC.
• 15.4. TrakCel Limited
• 15.5. Parkoursc Inc.
• 15.6. DHL
• 15.7. McKesson Corporation
• 15.8. Almac Group Limited
• 15.9. Catalent Inc.
• 15.10. Biostor Ltd.

16. Strategic Recommendations